Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals

Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, with the Healthcare and Materials contributing most losses. The Dow Jones Industrial Average declined 0.31 percent to close at 24,508.66, while the S&P 500 Index fell 0.41 percent to close at 2,652.01. The Nasdaq Composite Index decreased 0.28 percent to close at 6,856.53.

“This market has been going in lockstep with the progress made in the tax bill,” said Art Hogan, chief market strategist at B. Riley FBR. “When you see bumps in the road, you’re going to get some volatility.”

RDI Initiates Coverage on:

ImmunoCellular Therapeutics, Ltd.

Marinus Pharmaceuticals, Inc.

ImmunoCellular Therapeutics stock jumped 82.35% Thursday, to close the day at $0.40. The stock recorded a trading volume of 57,712,438 shares, which was above its three months average volume of 2,509,290 shares. The share price shot up on the news that the company achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. In the last year, ImmunoCellular Therapeutics shares have traded in a range of 0.17 – 4.27. The share price has gained 137.06% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.32 is below its 200-day moving average of $0.52. Shares of ImmunoCellular Therapeutics have gained roughly 21.39 percent in the past month and are down 80.34 percent year-to-date.

Access RDI’s ImmunoCellular Therapeutics, Ltd. Research Report at:

On Thursday, shares in Marinus Pharmaceuticals recorded a trading volume of 5,472,000 shares, which was above the three months average volume of 1,795,520 shares. The stock ended the day 15.47% higher at 9.33. The share price has gained 1,037.80% from its 52 week low with a 52 week trading range of 0.82 – 9.87.The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $6.75 is greater than its 200-day moving average of $3.92. Shares of Marinus Pharmaceuticals have gained roughly 42.44 percent in the past month and are up 823.76 percent year-to-date.

Access RDI’s Marinus Pharmaceuticals, Inc. Research Report at:

Our Actionable Research on ImmunoCellular Therapeutics, Ltd. (NYSEAMERICAN:IMUC) and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.